{"id":5400,"date":"2025-02-05T14:48:53","date_gmt":"2025-02-05T14:48:53","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=5400"},"modified":"2025-04-16T16:04:03","modified_gmt":"2025-04-16T16:04:03","slug":"enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/","title":{"rendered":"\u30a8\u30f3\u30e6\u30d5\u30a1\u30fc\u30de\u3001\u7cd6\u30da\u30d7\u30c1\u30c9\u6297\u4f53\u533b\u85ac\u54c1\u30674\u5104\u5186\u306e\u30b7\u30fc\u30c9\u8cc7\u91d1\u3092\u8abf\u9054"},"content":{"rendered":"

\u7cd6\u30da\u30d7\u30c1\u30c9\u3092\u65b0\u305f\u306a\u5275\u85ac\u30bf\u30fc\u30b2\u30c3\u30c8\u3068\u3057\u3066\u3001\u672a\u3060\u6cbb\u7642\u6cd5\u306e\u78ba\u7acb\u3055\u308c\u3066\u3044\u306a\u3044\u75be\u60a3\u306b\u5bfe\u3059\u308b\u533b\u85ac\u54c1\u958b\u767a\u3092\u76ee\u6307\u3059\u30a8\u30f3\u30e6\u30d5\u30a1\u30fc\u30de\u682a\u5f0f\u4f1a\u793e\u306f\u30012024\u5e7412\u6708\u306b\u4eac\u90fd\u5927\u5b66\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u30ad\u30e3\u30d4\u30bf\u30eb\u682a\u5f0f\u4f1a\u793e\u3001\u5927\u9d6c\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u30ba\u5408\u540c\u4f1a\u793e\u3001\u682a\u5f0f\u4f1a\u793eDG\u30a4\u30f3\u30ad\u30e5\u30d9\u30fc\u30b7\u30e7\u30f3\u3001\u682a\u5f0f\u4f1a\u793e\u5317\u6d77\u9053\u5171\u5275\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba\u3092\u5f15\u53d7\u5148\u3068\u3059\u308b\u7b2c\u4e09\u8005\u5272\u5f53\u5897\u8cc7\u3092\u5b9f\u65bd\u3057\u3001\u7dcf\u984d4\u5104\u5186\u306e\u30b7\u30fc\u30c9\u30e9\u30a6\u30f3\u30c9\u8cc7\u91d1\u3092\u8abf\u9054\u3057\u307e\u3057\u305f\u3002\u307e\u305f\u3001\u4eac\u90fd\u5927\u5b66\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u30fb\u30ad\u30e3\u30d4\u30bf\u30eb\u682a\u5f0f\u4f1a\u793e\u306e\u8fbb\u6751\u525b\u6c0f\u3001\u5927\u9d6c\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u30ba\u5408\u540c\u4f1a\u793e\u306e\u68ee\u6587\u9686\u6c0f\u304c\u65b0\u305f\u306b\u793e\u5916\u53d6\u7de0\u5f79\u306b\u5c31\u4efb\u3044\u305f\u3057\u307e\u3057\u305f\u3002<\/p>

\u672c\u8cc7\u91d1\u8abf\u9054\u306e\u76ee\u7684<\/strong><\/p>

\u4eca\u56de\u306e\u8abf\u9054\u8cc7\u91d1\u306f\u3001\u5317\u6d77\u9053\u5927\u5b66\u5927\u5b66\u9662\u306e\u897f\u6751\u771f\u4e00\u90ce\u6559\u6388\u304c\u767a\u898b\u3057\u305f\u7cd6\u30da\u30d7\u30c1\u30c9\u3092\u6a19\u7684\u3068\u3057\u305f\u753b\u671f\u7684\u306a\u6297\u539f\u63d0\u793a\u6cd5\u306b\u57fa\u3065\u304f\u3001\u9078\u629e\u6027\u306e\u9ad8\u3044\u6297\u4f53\u533b\u85ac\u3092\u5275\u88fd\u3059\u308b\u6280\u8853\u306e\u5b9f\u7528\u5316\u306b\u5411\u3051\u305f\u30ad\u30c3\u30af\u30aa\u30d5\u8cc7\u91d1\u3068\u3057\u3066\u6d3b\u7528\u3055\u308c\u307e\u3059\u3002\u5177\u4f53\u7684\u306b\u306f\u3001\u304c\u3093\u3060\u3051\u3067\u306a\u304f\u3001\u81ea\u5df1\u514d\u75ab\u75be\u60a3\u3084\u8a8d\u77e5\u75c7\u306a\u3069\u5e45\u5e83\u3044\u75be\u60a3\u306b\u5bfe\u3057\u3066\u3001\u5fc5\u8981\u306a\u4eba\u306b\u5fc5\u8981\u306a\u85ac\u3092\u8fc5\u901f\u306b\u5c4a\u3051\u308b\u3053\u3068\u3092\u4fc3\u9032\u3059\u308b\u305f\u3081\u306e\u8cc7\u6e90\u3068\u3057\u3066\u6d3b\u7528\u3055\u308c\u307e\u3059\u3002<\/p>

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a NEC\u3068\u30d0\u30a4\u30aa\u30df\u30fc\u3001\u30c7\u30b8\u30bf\u30eb\u75c5\u7406\u5206\u91ce\u306b\u304a\u3051\u308b\u89e3\u6790\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u958b\u767a\u30fb\u62e1\u5927\u3067\u63d0\u643a<\/a><\/strong><\/h3>

\u95a2\u4fc2\u8005\u304b\u3089\u306e\u30b3\u30e1\u30f3\u30c8<\/strong><\/p>

\u4ee3\u8868\u53d6\u7de0\u5f79\u793e\u9577 \u5b89\u4e95\u5fe0\u826f<\/strong><\/p>

\u4eca\u56de\u306e\u8cc7\u91d1\u8abf\u9054\u3092\u5b8c\u4e86\u3067\u304d\u305f\u3053\u3068\u3092\u975e\u5e38\u306b\u559c\u3070\u3057\u304f\u601d\u3063\u3066\u304a\u308a\u3001\u6295\u8cc7\u3057\u3066\u304f\u3060\u3055\u3063\u305f\u3059\u3079\u3066\u306e\u4f01\u696d\u306b\u5fc3\u304b\u3089\u611f\u8b1d\u7533\u3057\u4e0a\u3052\u307e\u3059\u3002<\/p>

\u5f53\u793e\u306f2019\u5e74\u306e\u5275\u696d\u4ee5\u6765\u3001\u9577\u5e74\u7814\u7a76\u3057\u3066\u304d\u305f\u7cd6\u9396\u89e3\u6790\u6280\u8853\u3084\u6297\u539f\u63d0\u793a\u6cd5\u3092\u533b\u85ac\u54c1\u7814\u7a76\u958b\u767a\u306b\u5fdc\u7528\u3067\u304d\u308b\u3088\u3046\u3001\u7cbe\u5ea6\u30fb\u6a5f\u80fd\u30fb\u6280\u8853\u306e\u5411\u4e0a\u306b\u52aa\u3081\u3066\u307e\u3044\u308a\u307e\u3057\u305f\u3002\u75be\u60a3\u7279\u7570\u7684\u306a\u7cd6\u9396\u69cb\u9020\u306e\u5f79\u5272\u306e\u89e3\u6790\u306f\u3001\u4ed6\u793e\u3092\u51cc\u99d5\u3059\u308b\u30ec\u30d9\u30eb\u306b\u9054\u3057\u3066\u3044\u308b\u3068\u8003\u3048\u3066\u304a\u308a\u307e\u3059\u3002<\/p>

\u6b21\u306e\u30b9\u30c6\u30fc\u30b8\u306f\u3001\u79c1\u305f\u3061\u306e\u6280\u8853\u3092\u533b\u85ac\u54c1\u958b\u767a\u306b\u5fdc\u7528\u3059\u308b\u3053\u3068\u3067\u3042\u308a\u3001\u305d\u306e\u305f\u3081\u306b\u3082\u4eca\u56de\u306e\u8cc7\u91d1\u8abf\u9054\u306f\u4e0d\u53ef\u6b20\u3067\u3057\u305f\u3002\u3053\u306e\u8cc7\u91d1\u3068\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u306e\u7686\u69d8\u306e\u3054\u6307\u5c0e\u306e\u3082\u3068\u3001\u3088\u308a\u6709\u52b9\u306a\u6297\u4f53\u533b\u85ac\u54c1\u3092\u4e00\u65e5\u3082\u65e9\u304f\u60a3\u8005\u3055\u3093\u306b\u304a\u5c4a\u3051\u3067\u304d\u308b\u3088\u3046\u3001\u5168\u529b\u3092\u5c3d\u304f\u3057\u3066\u307e\u3044\u308a\u307e\u3059\u3002<\/p>

Tsuyoshi Tsujimura, Manager of the Investment Department at Kyoto University Innovation Capital Co., Ltd.　<\/strong><\/p>

Enyu Pharma Co., Ltd. has the ability to discover new drug discovery targets by utilizing its unique glycan analysis technology. This technology enables the development of groundbreaking antibody drugs even in areas where treatment has been difficult until now by deeply understanding the structural role of glycans in disease. In addition, the company’s antibody production technology has the potential to dramatically change the concept of antibody drugs by quickly and efficiently producing pharmaceutical antibodies with enhanced disease and tissue specificity through the acquisition of precision glycan-specific antibodies that have been difficult to obtain until now.<\/p>

\u4eac\u90fd\u5927\u5b66\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u30ad\u30e3\u30d4\u30bf\u30eb\u682a\u5f0f\u4f1a\u793e\u306f\u3001\u672c\u51fa\u8cc7\u3092\u901a\u3058\u3066\u3001\u304c\u3093\u3092\u306f\u3058\u3081\u3068\u3059\u308b\u30a2\u30f3\u30e1\u30c3\u30c8\u30e1\u30c7\u30a3\u30ab\u30eb\u30cb\u30fc\u30ba\u306e\u9ad8\u3044\u96e3\u6cbb\u6027\u75be\u60a3\u306b\u5bfe\u3059\u308b\u65b0\u305f\u306a\u6cbb\u7642\u6cd5\u306e\u5b9f\u73fe\u306b\u8ca2\u732e\u3059\u308b\u3053\u3068\u3092\u76ee\u6307\u3057\u307e\u3059\u3002\u7279\u306b\u3001\u7cd6\u9396\u89e3\u6790\u6280\u8853\u3092\u7528\u3044\u305f\u65b0\u305f\u306a\u5275\u85ac\u30bf\u30fc\u30b2\u30c3\u30c8\u306e\u767a\u898b\u3068\u3001\u305d\u308c\u306b\u57fa\u3065\u304f\u75be\u60a3\u7279\u7570\u7684\u306a\u6297\u4f53\u533b\u85ac\u306e\u958b\u767a\u306f\u3001\u3053\u308c\u307e\u3067\u6cbb\u7642\u306e\u9078\u629e\u80a2\u304c\u9650\u3089\u308c\u3066\u3044\u305f\u60a3\u8005\u3055\u3093\u306b\u5e0c\u671b\u3092\u3082\u305f\u3089\u3059\u3082\u306e\u3068\u78ba\u4fe1\u3057\u3066\u304a\u308a\u307e\u3059\u3002<\/p>

Fumitaka Mori Partner , Taiho Innovations LLC　<\/strong><\/p>

When I first heard about Enyu Pharma two years ago, I was deeply impressed by their innovative technology that enables previously difficult drug discovery by capturing disease-specific dynamic epitopes (glycopeptides). Since then, we have had many discussions about the approach and implementation structure of drug discovery, and I am truly happy to be able to embark on a new drug discovery challenge together in the form of investment. Enyu Pharma’s drug discovery platform enables early diagnosis and therapeutic intervention of cancer, and has the potential to realize the grand dream of a complete cure. Taiho Innovations will do its utmost to support them in making this dream a reality, with the goal of bringing smiles to the faces of patients around the world.<\/p>

\u30bd\u30fc\u30b9 PR TIMES<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"

Enyu Pharma Co., Ltd., which aims to develop medicines for diseases for which there are no outstanding treatments using glycopeptides as a new drug discovery target, raised a total of 400 million yen in a seed round in December 2024 through a third-party allotment of new shares to Kyoto University Innovation Capital Co., Ltd., Taiho Innovations LLC, DG Incubation Inc., and Hokkaido Co-Creation Partners Inc. In addition, Tsuyoshi Tsujimura of Kyoto University Innovation Capital Co., Ltd. and Fumitaka Mori of Taiho Innovations LLC have been appointed as new outside directors.Purpose of this fundraisingThe funds raised will be used to kick off the practical application of a technology to discover highly […]<\/p>\n","protected":false},"author":4,"featured_media":5422,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[208,1,89,198,211,237,182,206],"tags":[805,803,804,497,493,105,106,424],"ppma_author":[205],"class_list":["post-5400","post","type-post","status-publish","format-standard","has-post-thumbnail","category-apac","category-fintech","category-health-tech","category-investments","category-japan","category-news","category-pharma","category-regional","tag-antibody-drugs","tag-enyu-pharma","tag-glycopeptides","tag-healthtech","tag-investments","tag-itbusinesstoday","tag-news","tag-pharma"],"yoast_head":"\nEnyu Pharma Raises 400M Yen in Seed Funding<\/title>\n<meta name=\"description\" content=\"Enyu Pharma raises 400 million yen in seed funding for glycopeptide-based drug discovery and appoints new outside directors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enyu Pharma Raises 400M Yen in Seed Funding\" \/>\n<meta property=\"og:description\" content=\"Enyu Pharma raises 400 million yen in seed funding for glycopeptide-based drug discovery and appoints new outside directors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-05T14:48:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-16T16:04:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Enyu-Pharma_-a-company-developing-antibody-drugs-using-glycopeptides-as-a-new-drug-discovery-target_-raises-a-total-of-400-million-yen-in-seed-funding.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30a8\u30f3\u30e6\u30d5\u30a1\u30fc\u30de\u3001\u30b7\u30fc\u30c9\u8cc7\u91d1\u3068\u3057\u30664\u5104\u5186\u3092\u8abf\u9054","description":"\u30a8\u30f3\u30e6\u30d5\u30a1\u30fc\u30de\u3001\u7cd6\u30da\u30d7\u30c1\u30c9\u5275\u85ac\u3067\u30b7\u30fc\u30c9\u8cc7\u91d14\u5104\u5186\u3092\u8abf\u9054\u3001\u65b0\u793e\u5916\u53d6\u7de0\u5f79\u3092\u9078\u4efb.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/","og_locale":"ja_JP","og_type":"article","og_title":"Enyu Pharma Raises 400M Yen in Seed Funding","og_description":"Enyu Pharma raises 400 million yen in seed funding for glycopeptide-based drug discovery and appoints new outside directors.","og_url":"https:\/\/itbusinesstoday.com\/ja\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/","og_site_name":"itbusinesstoday","article_published_time":"2025-02-05T14:48:53+00:00","article_modified_time":"2025-04-16T16:04:03+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Enyu-Pharma_-a-company-developing-antibody-drugs-using-glycopeptides-as-a-new-drug-discovery-target_-raises-a-total-of-400-million-yen-in-seed-funding.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Enyu Pharma Raises 400M Yen in Seed Funding for Glycopeptide Antibody Drugs","datePublished":"2025-02-05T14:48:53+00:00","dateModified":"2025-04-16T16:04:03+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/"},"wordCount":662,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Enyu-Pharma_-a-company-developing-antibody-drugs-using-glycopeptides-as-a-new-drug-discovery-target_-raises-a-total-of-400-million-yen-in-seed-funding.webp","keywords":["antibody drugs","Enyu Pharma","glycopeptides","Healthtech","Investments","itbusinesstoday","News","Pharma"],"articleSection":["APAC","FinTech","Health Tech","Investments","Japan","News","Pharma","Regional"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/","url":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/","name":"\u30a8\u30f3\u30e6\u30d5\u30a1\u30fc\u30de\u3001\u30b7\u30fc\u30c9\u8cc7\u91d1\u3068\u3057\u30664\u5104\u5186\u3092\u8abf\u9054","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Enyu-Pharma_-a-company-developing-antibody-drugs-using-glycopeptides-as-a-new-drug-discovery-target_-raises-a-total-of-400-million-yen-in-seed-funding.webp","datePublished":"2025-02-05T14:48:53+00:00","dateModified":"2025-04-16T16:04:03+00:00","description":"\u30a8\u30f3\u30e6\u30d5\u30a1\u30fc\u30de\u3001\u7cd6\u30da\u30d7\u30c1\u30c9\u5275\u85ac\u3067\u30b7\u30fc\u30c9\u8cc7\u91d14\u5104\u5186\u3092\u8abf\u9054\u3001\u65b0\u793e\u5916\u53d6\u7de0\u5f79\u3092\u9078\u4efb.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Enyu-Pharma_-a-company-developing-antibody-drugs-using-glycopeptides-as-a-new-drug-discovery-target_-raises-a-total-of-400-million-yen-in-seed-funding.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/02\/Enyu-Pharma_-a-company-developing-antibody-drugs-using-glycopeptides-as-a-new-drug-discovery-target_-raises-a-total-of-400-million-yen-in-seed-funding.webp","width":1200,"height":800,"caption":"Enyu Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/fintech\/enyu-pharma-raises-400m-yen-in-seed-funding-for-glycopeptide-antibody-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Enyu Pharma Raises 400M Yen in Seed Funding for Glycopeptide Antibody Drugs"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"author_category":"","first_name":"NewsDesk","last_name":"","user_url":"https:\/\/itbusinesstoday.com","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/5400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=5400"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/5400\/revisions"}],"predecessor-version":[{"id":5401,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/5400\/revisions\/5401"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/5422"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=5400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=5400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=5400"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=5400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}